BeOne Medicines (BEIGF) Non-Current Debt (2015 - 2026)

BeOne Medicines (BEIGF) has reported Non-Current Debt for 12 consecutive years, with $882.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 503.84% year-over-year to $882.2 million in Q2 2026; TTM through Jun 2026 was $882.2 million, a 503.84% increase from a year earlier, with the FY2025 full-year figure at $961.9 million, up 477.78% from the prior year.
• Non-Current Debt was $882.2 million for Q2 2026 at BeOne Medicines, down from $962.5 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $962.5 million in Q1 2026 and troughed at $146.1 million in Q2 2025.
• A 5-year average of $350.1 million and a median of $202.0 million in 2022 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt retreated 21.15% in 2025 and jumped 503.84% in 2026, its largest moves.
• Over 5 years, Non-Current Debt stood at $209.1 million in 2022, then retreated by 5.51% to $197.6 million in 2023, then fell by 15.75% to $166.5 million in 2024, then jumped by 477.78% to $961.9 million in 2025, then dropped by 8.29% to $882.2 million in 2026.
• The last three Non-Current Debt figures came in at $882.2 million (Q2 2026), $962.5 million (Q1 2026), and $961.9 million (Q4 2025), per Business Quant data.